

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

STRATEGIC INVESTMENT IN SUTRA MEDICAL

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that Peijia Medical (Suzhou) Co., Ltd. (沛嘉醫療科技(蘇州)有限公司) (“**Peijia Suzhou**”), a wholly owned subsidiary of the Company, recently entered into a Stock Purchase Agreement (the “**Agreement**”) with Sutra Medical, Inc. (“**Sutra Medical**”), a Delaware corporation (f/k/a Dura, LLC), and certain other parties, and has assigned all of its rights and obligations under the Purchase Agreement to its wholly owned subsidiary, Peijia Medical Holding Limited (“**Peijia Holding**”). The initial closing of the purchase and sale of shares of Sutra Medical by Peijia Holding occurred in August, 2021, and Peijia Holding is currently the second largest shareholder of Sutra Medical, after the founding team of Sutra Medical. According to the Agreement, upon achievement of certain milestones, Peijia Medical Holding Limited shall purchase certain additional shares of Sutra Medical. In addition, the Company has right of first offer if Sutra Medical proposes to offer or sell any new securities, subject to certain customary exceptions.

Founded in 2012 and currently headquartered in Lake Forest, California, Sutra Medical designs and develops transcatheter solutions to treat valvular heart disease. Its founding team has extensive experience in both academia and industry. Sutra Medical’s key product candidate, Sutra Hemi Valve, is a transcatheter mitral valve therapeutic device that adopts a hybrid approach between valve replacement and repair technology. The device is designed to treat mitral valve regurgitation using a coaptation augmentation technology that targets only the posterior mitral valve leaflet. Sutra Hemi Valve is currently in the preclinical evaluation stage. Early preclinical results show good leaflet coaptation and no central mitral regurgitation at 120 days post implantation in animals.

The existing shareholders of Sutra are independent third parties. The Board believes that this strategic investment in Sutra will further strengthen the Company's product pipeline in transcatheter heart valves.

As all applicable percentage ratios under Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") in relation to the transaction are respectively less than 5%, the transaction does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, August 27, 2021

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, and Mr. Wai Ming Yip as independent non-executive Directors.